The Controlled Substances Act leaves pathway for intoxicating hemp-derived cannabinoids

Delta-8 THC exploded onto the scene in 2019, followed by delta-10 THC, THC-O acetate and HHC in 2020 and 2021.

While state regulatory agencies have opted for a whack-a-mole approach that focuses on controlling one cannabinoid at a time, the federal government has been largely silent on the legal status of hemp-derived cannabinoids.

Marijuana products technically aren’t eligible for federal trademarks because the plant is illegal under the Controlled Substances Act

Marijuana products technically aren’t eligible for federal trademarks because the plant is illegal under the Controlled Substances Act.

But that doesn’t mean cannabis businesses can’t protect their intellectual property and build brand awareness through patents and federal trademarks—the latter is applicable if the application doesn’t involve a plant-touching side of the business.

‘No reason’ for DEA to delay marijuana rescheduling, FDA chief says

There’s “no reason” for the U.S. Drug Enforcement Administration to delay its long-awaited decision on moving marijuana from Schedule 1 to Schedule 3 of the Controlled Substances Act, the head of the Food and Drug Administration told a House committee.

Colorado marijuana growers can access more diverse genetics

Colorado’s marijuana cultivators now have freedom to procure genetics from a wider variety of sources.

Republican senators oppose marijuana rescheduling based on global treaties

Moving marijuana to Schedule 3 of the Controlled Substances Act, as Biden administration health officials have recommended, violates U.S. promises to other countries.

Calling marijuana a ‘gateway drug,’ House GOP opposes banking reform

Congressional Republicans should oppose marijuana reform, including banking protections, because MJ is a “dangerous, addictive … gateway drug,” according to a GOP policy memo.

Mushroom Joe? How President Biden could reschedule psilocybin like marijuana

President Joe Biden or a successor could reschedule psychedelics like marijuana, but only if states create the right psilocybin policies.

Marijuana ETF shutting down not long after launch

Marijuana sector exchange traded fund Subversive Cannabis ETF will close down as of March 28, only half a year after launching.

280E, new markets and wholesale revenue highlight cannabis earnings season

Tax strategies took the spotlight in fourth-quarter financial reports from publicly traded U.S. cannabis companies.

TerrAscend expects $26 million tax refund, shares strategy for marijuana nemesis 280E

TerrAscend Corp. is the latest marijuana multistate operator to announce a plan to stop paying taxes owed under Section 280E of the Internal Revenue Code, and an executive hinted at the company’s legal basis for doing so.

Exploring cannabis as medicine: Q&A with researcher Jean Talleyrand

California-based Jean Talley sat down with MJBizDaily to share his perspective about medical cannabis research.